GlassScriptPhysician profile
Barbara Ann Mcintosh
NPI 1982652103
$18,393.88
in general payments reported to CMS, 2019-2025
40 companies · $3,967 in 2025
The $3,967 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,629 · 2021: $2,017 · 2022: $2,424 · 2023: $3,181 · 2024: $3,478 · 2025: $3,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,048.34 |
| Education | $577.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,303.50 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $3,085.55 | 2019-2025 | |
| Janssen Biotech, INC. | $2,009.82 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,057.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,000.51 | 2019-2025 | Orencia |
| Ucb, INC. | $868.75 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $803.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $619.94 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $561.86 | 2019-2023 | Krystexxa |
| Sobi, INC | $519.86 | 2019-2025 | |
| Genzyme Corporation | $451.37 | 2020-2025 | |
| Lilly USA, LLC | $411.25 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $319.53 | 2021-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $302.16 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.96 | 2020-2023 | Cyltezo, Ofev |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $292.08 | 2023-2025 | Hadlima, Renflexis |
| Actelion Pharmaceuticals US, INC. | $276.65 | 2019-2025 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $263.67 | 2019-2025 | Strensiq |
| Glaxosmithkline, LLC. | $235.25 | 2019-2025 | Benlysta |
| Radius Health, INC. | $226.41 | 2020-2025 | Tymlos |
| Genentech USA, INC. | $210.60 | 2019-2025 | Actemra, Gazyva |
| Fresenius Kabi USA, LLC | $196.36 | 2023-2025 | Idacio |
| Alvogen INC | $156.03 | 2022-2025 | Teriparatide |
| Ani Pharmaceuticals, INC. | $152.85 | 2024-2025 | Purified Cortrophin Gel |
| Antares Pharma, INC. | $124.51 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $102.19 | 2021-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $87.88 | 2024 | Arcalyst |
| Octapharma USA, INC. | $71.59 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Kiniksa Pharmaceuticals, LTD. | $49.90 | 2022-2023 | Arcalyst |
| Arcutis Biotherapeutics, INC. | $39.77 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $39.76 | 2019 | |
| Pacira Therapeutics, INC. | $37.73 | 2019 | |
| Hospira, INC. | $37.33 | 2024-2025 | |
| Kyowa Kirin, INC. | $35.80 | 2023-2025 | Crysvita |
| Eisai INC. | $34.95 | 2024 | |
| Mylan Institutional INC. | $33.70 | 2023 | Hulio |
| Oyster Point Pharma, INC. | $25.13 | 2024 | Tyrvaya |
| Tonix Medicines, INC. | $21.20 | 2025 | Tonmya |
| Teva Pharmaceuticals USA, INC. | $17.51 | 2024 | Truxima |
| Celltrion USA INC. | $14.16 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Mcintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.